[go: up one dir, main page]

AR128868A1 - Formulaciones de inhibidor de tyk2 y métodos para elaborarlas - Google Patents

Formulaciones de inhibidor de tyk2 y métodos para elaborarlas

Info

Publication number
AR128868A1
AR128868A1 ARP230100725A ARP230100725A AR128868A1 AR 128868 A1 AR128868 A1 AR 128868A1 AR P230100725 A ARP230100725 A AR P230100725A AR P230100725 A ARP230100725 A AR P230100725A AR 128868 A1 AR128868 A1 AR 128868A1
Authority
AR
Argentina
Prior art keywords
preparing
methods
inhibitor formulations
tyk2 inhibitor
tyk2
Prior art date
Application number
ARP230100725A
Other languages
English (en)
Inventor
Alan John Collis
Stuart Levy Levy
Colin Minchom
Andrew Phimister
Sarah Jean Bethune
David Shank Fry
Erica Schlesinger
Dan Smithey
Randy Wald
James Fennewald
Original Assignee
Nimbus Lakshmi Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nimbus Lakshmi Inc filed Critical Nimbus Lakshmi Inc
Publication of AR128868A1 publication Critical patent/AR128868A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Reivindicación 1: Una composición farmacéutica, formulación o forma de dosificación unitaria que comprende: (a) Compuesto (1) o un solvato de este, o una sal farmacéuticamente aceptable de este; (b) uno o más rellenos o diluyentes; (c) uno o más solubilizantes; y (d) uno o más aglutinantes.
ARP230100725A 2022-03-25 2023-03-23 Formulaciones de inhibidor de tyk2 y métodos para elaborarlas AR128868A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202263269945P 2022-03-25 2022-03-25

Publications (1)

Publication Number Publication Date
AR128868A1 true AR128868A1 (es) 2024-06-19

Family

ID=88102038

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP230100725A AR128868A1 (es) 2022-03-25 2023-03-23 Formulaciones de inhibidor de tyk2 y métodos para elaborarlas

Country Status (9)

Country Link
US (1) US20250221997A1 (es)
EP (1) EP4499103A4 (es)
JP (1) JP2025510859A (es)
CN (1) CN118922192A (es)
AR (1) AR128868A1 (es)
CO (1) CO2024014215A2 (es)
PE (1) PE20250748A1 (es)
TW (1) TW202341989A (es)
WO (1) WO2023183900A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025191534A1 (en) * 2024-03-14 2025-09-18 Assia Chemical Industries Ltd. Solid state forms of zasocitinib and process for preparation thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3043609A1 (en) * 2016-11-16 2018-05-24 Abide Therapeutics, Inc. Pharmaceutical formulations
ES2994013T3 (en) * 2017-07-28 2025-01-15 Takeda Pharmaceuticals Co Tyk2 inhibitors and uses thereof
AU2019360941B2 (en) * 2018-10-15 2025-02-27 Takeda Pharmaceutical Company Limited TYK2 inhibitors and uses thereof
EP3870183A4 (en) * 2018-10-26 2022-07-20 Merck Sharp & Dohme Corp. FORMULATIONS OF ANTIVIRAL COMPOUNDS
EP4031110B1 (en) * 2019-09-18 2025-12-24 Bristol-Myers Squibb Company Dosage forms for tyk2 inhibitors

Also Published As

Publication number Publication date
CN118922192A (zh) 2024-11-08
US20250221997A1 (en) 2025-07-10
WO2023183900A1 (en) 2023-09-28
TW202341989A (zh) 2023-11-01
CO2024014215A2 (es) 2025-02-24
EP4499103A1 (en) 2025-02-05
JP2025510859A (ja) 2025-04-15
PE20250748A1 (es) 2025-03-13
EP4499103A4 (en) 2025-09-24

Similar Documents

Publication Publication Date Title
AR122351A1 (es) Derivados de metilquinazolinona como inhibidores de braf
CR20220281A (es) Derivados de pirazolilo útiles como agentes anti-cancerígenos
ZA202006378B (en) N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition thereof, and use thereof
CO2024001367A2 (es) Compuestos antivirales
AR063096A1 (es) Pirazolopirimidinas como inhibidores de quinasa dependientes de ciclina
BR112022009209A2 (pt) Derivado de amida e método de preparação e uso do mesmo na medicina
AR058780A1 (es) Imidazopirazinas como inhibidores de quinasas dependientes de ciclina
ZA202311035B (en) Phosphonyl derivative, and composition and pharmaceutical application thereof
MX2009001659A (es) Compuestos de 2,5-dihidroxibenceno para el tratamiento de rosacea.
AR134265A1 (es) Heterociclos y usos de los mismos
ZA202400988B (en) Aak1 inhibitor and use thereof
AR131639A1 (es) Inhibidores de kif18a y usos de los mismos
CO2021017202A2 (es) Compuestos tricíclicos
UY29085A1 (es) Derivados de pirimidina 4-sulfonamido sustituidos, compuestos intermedios para su preparación, procedimientos de preparación, composiciones medicinales conteniéndolos y aplicaci0nes
BR112023026909A2 (pt) Sal farmaceuticamente aceitável de ap1189 ((e)-n-[1-(2-nitrofenil)-1-h-pirrol-2-il-alilidenoamino]-guanidina), composição farmacêutica, forma de dosagem única, e, formulação oral
AR128932A1 (es) Inhibidores de bcl-xl
AR128868A1 (es) Formulaciones de inhibidor de tyk2 y métodos para elaborarlas
AR133240A1 (es) Compuestos, composiciones y métodos
AR133241A1 (es) Compuestos, composiciones y métodos
MX2024011179A (es) Compuestos multiciclicos
CO2022008616A2 (es) Composición farmacéutica oral que comprende compuesto de carbamato y método de preparación para la misma
AR131906A1 (es) Compuestos terapéuticos
AR130828A1 (es) Método para tratar el cáncer
CO2026000093A2 (es) Composiciones farmacéuticas para inhibidores de la cinasa nek7
MX2025005392A (es) Composicion farmaceutica que comprende un inhibidor de aak1